Drug Index


Mechanism :

Exact mechanism unknown; likely interaction with phospholipids and steroids in parasitic cell membranes, inhibition of cytochrome c oxidase (mitochondrial function), and apoptosis-like cell death.

Indication :

  • Leishmaniasis: In adolescents 12 years and older weighing at least 30 kg.
  • Off-label: Free-living amebae (FLA) infections, including primary amoebic meningoencephalitis (PAM) caused by Naegleria fowleri, granulomatous amoebic encephalitis caused by Balamuthia mandrillaris, and Acanthamoeba spp.

Contraindications :

Hypersensitivity to miltefosine or any component of the formulation; Sjogren-Larsson syndrome; pregnancy.

Dosing :

Oral Use in children ≥12 years
30 to 44 kg:
50 mg twice daily for 28 days.
≥45 kg:
50 mg 3 times daily for 28 days.

Adverse Effect :

Headache, dizziness, nausea, vomiting, diarrhea, abdominal pain, thrombocytopenia, increased serum transaminases, creatinine, pruritus, cellulitis, pyoderma, testicular pain and swelling.

Interaction :

No known significant interactions.

Hepatic Dose :

Specific guidelines for dosage adjustments in hepatic impairment are not available.
02/14/2024 21:30:30 Miltefosine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0